var data={"title":"Zanamivir: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Zanamivir: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7176?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">see &quot;Zanamivir: Drug information&quot;</a> and <a href=\"topic.htm?path=zanamivir-patient-drug-information\" class=\"drug drug_patient\">see &quot;Zanamivir: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50907065\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Influenza Update</span>\n      <span class=\"collapsible-date\">January 2018</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The Centers for Disease Control and Prevention (CDC) is reporting a significant increase in influenza activity over recent weeks, with influenza A(H3N2) viruses predominating. Past A(H3N2) virus-predominant influenza seasons have been associated with more hospitalizations and deaths in persons 65 years of age and older, as well as in young children, compared to other age groups. Influenza vaccine effectiveness has also been generally lower against A (H3N2) viruses than against influenza A (H1N1) pdm09 or influenza B viruses. Last influenza season, vaccine effectiveness against circulating A (H3N2) viruses was estimated to be 32% in the US and is expected to be similar this season if the same A (H3N2) viruses continue to predominate. Influenza activity was high in the Southern Hemisphere in 2017 and preliminary data from Australia suggest overall vaccine effectiveness of 33% but only 10% against A (H3N2) viruses, making the use of antiviral medications for treatment of influenza, in addition to preventive vaccination, even more important.</p>\n        <p style=\"text-indent:0em;\">The CDC has also issued a health advisory stating that all hospitalized patients, patients with severe, complicated, or progressive illness (including outpatients), and all high-risk patients (including pediatric patients younger than 2 years; adults 65 years and older; patients with certain chronic illnesses or neurologic or neurodevelopmental conditions; immunosuppressed patients; women who are pregnant or postpartum (within 2 weeks of delivery); patients younger than 19 years of age receiving long term aspirin therapy; American Indians/Alaska Natives; patients with BMI of 40 or more; and residents of nursing homes or other chronic-care facilities) with suspected or confirmed influenza should be treated as soon as possible with a neuraminidase inhibitor antiviral (eg, oseltamivir, peramivir, zanamivir). Adamantanes (eg, amantadine, rimantadine) are not currently recommended for treatment or prophylaxis of influenza A because of high levels of resistance. Antivirals for influenza work best when initiated within 48 hours of illness onset; however, clinical benefit has been observed even when treatment is initiated later in some patients.</p>\n        <p style=\"text-indent:0em;\">Further information is available at <a target=\"_blank\" href=\"https://emergency.cdc.gov/han/han00409.asp&amp;token=/XpciKoGXD/NBcI56myByIrj6XDzXmi2bFm6I7VYATsTAoPzpN4M+ut5dGKrD6OM&amp;TOPIC_ID=13079\" target=\"_blank\">https://emergency.cdc.gov/han/han00409.asp</a> and <a target=\"_blank\" href=\"https://www.cdc.gov/flu/weekly/summary.htm&amp;token=R4Uiw8/bmPVaqNHRDqpXLOtzxb+vTZhOOrHrvoZzklFBp7r1xCTELF4KBDcLrJouICpPDwRTIgOkmOCDxEXvOQ==&amp;TOPIC_ID=13079\" target=\"_blank\">https://www.cdc.gov/flu/weekly/summary.htm</a>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235668\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Relenza Diskhaler</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235669\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Relenza</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1042836\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiviral Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Neuraminidase Inhibitor</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1042868\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">see &quot;Zanamivir: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>Note:</b> 10 mg dose is provided by 2 inhalations (one 5 mg blister per inhalation): </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Influenza virus A and B; treatment:</b> Oral inhalation: Children &ge;7 years and Adolescents: Two inhalations (10 mg) twice daily for 5 days; doses on first day should be separated by at least 2 hours; on subsequent days, doses should be spaced by ~12 hours. Begin within 2 days of signs or symptoms. Longer treatment may be considered for patients who remain severely ill after 5 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Influenza virus A and B; prophylaxis:</b> Oral inhalation: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">\n      <i>Household setting:</i> Children &ge;5 years and Adolescents: Two inhalations (10 mg) once daily for 10 days; begin within 36 hours following onset of signs or symptoms of  index case </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">\n      <i>Community outbreak:</i> Adolescents: Two inhalations (10 mg) once daily for 28 days; begin within 5 days of outbreak</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Alternate dosing:  Children &ge;5 years and Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">\n      <i>Household setting:</i> CDC Recommendation: Two inhalations (10 mg) once daily for 7 days after last known exposure (CDC, 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">\n      <i>Community outbreak:</i> IDSA/PIDS recommendations: Two inhalations (10 mg) once daily; continue until influenza activity in community subsides or immunity obtained from immunization; up to 28 days has been well tolerated (Bradley, 2011; CDC, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">\n      <i>Institutional outbreak:</i> CDC recommendations: Two inhalations (10 mg) once daily; continue for &ge;2 weeks and until ~7 days after identification of illness onset in the last patient. Zanamivir is to be used to control institutional outbreaks of influenza when circulating strains are suspected of being resistant to oseltamivir (CDC, 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">\n      <i>HIV-exposed/-positive:</i> Two inhalations (10 mg) once daily for 10 days after last known exposure (DHHS [pediatric], 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adult: <b>Influenza virus A and B:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Manufacturer's labeling: Oral inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Prophylaxis, household setting: Two inhalations (10 mg) once daily for 10 days. Begin within 36 hours following onset of signs or symptoms of index case.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Prophylaxis, community outbreak: Two inhalations (10 mg) once daily for 28 days. Begin within 5 days of outbreak.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Treatment: Two inhalations (10 mg total) twice daily for 5 days. Doses on first day should be separated by at least 2 hours; on subsequent days, doses should be spaced by ~12 hours. Begin within 2 days of signs or symptoms. Longer treatment may be considered for patients who remain severely ill after 5 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Alternate dosing: Oral inhalation: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Prophylaxis, household exposure: Two inhalations (10 mg) once daily for 7 days after last known exposure (CDC, 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Prophylaxis, institutional outbreak: Two inhalations (10 mg) once daily; continue for &ge;2 weeks and until ~7 days after identification of illness onset in the last patient. Zanamivir is to be used to control institutional outbreaks of influenza when circulating strains are suspected of being resistant to oseltamivir (CDC, 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Prophylaxis, community outbreak (IDSA/PIDS, 2011): Two inhalations (10 mg) once daily; continue until influenza activity in community subsides or immunity obtained from immunization; up to 28 days has been well tolerated (CDC, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in renal impairment:</b> Children, Adolescents, and Adults: Adjustment not necessary following a 5-day course of treatment due to low systemic absorption; however, the potential for drug accumulation should be considered. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235648\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Aerosol Powder Breath Activated, Inhalation: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Relenza Diskhaler: 5 mg/blister (20 ea) [contains lactose]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235634\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11217378\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Zanamivir <i>aqueous solution</i> intended for intravenous (IV) administration is <b>not</b> currently approved for use. Data on safety and efficacy via this route of administration are limited. However, limited supplies of zanamivir aqueous solution may be made available through the Zanamivir Compassionate Use Program for qualifying patients for the treatment of serious influenza illness.  For information, contact the GlaxoSmithKline Clinical Support Help Desk at 1-866-341-9160 or gskclinicalsupportHD@gsk.com.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1042872\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral Inhalation: <b>Inhalation powder not for use via nebulizer:</b> Use a Diskhaler&reg; delivery device (a special breath-activated plastic inhaler). The foil blister disk containing zanamivir inhalation powder should not be manipulated or solubilized. Load Relenza&reg; Rotadisk&reg; into the diskhaler; a blister that contains medication is pierced and the drug is dispersed into the air stream created when the patient inhales through the mouthpiece. Patients scheduled to take inhaled bronchodilators at the same time as zanamivir should be advised to use their bronchodilator before taking zanamivir. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235665\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Do not puncture blister until taking a dose using the Diskhaler.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1042837\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of influenza A or B infection in patients who have been symptomatic for no more than 2 days (FDA approved in children &ge;7 years and adults); prophylaxis of influenza A or B infection (FDA approved in children &ge;5 years and adults); has also been used for treatment of patients symptomatic for &gt;2 days with severe illness (CDC, 2010) </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The Advisory Committee on Immunization Practices (ACIP) recommends that antiviral <b>treatment</b> be considered for the following (see specific antiviral product monograph for appropriate patient selection):</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">&bull; Persons with severe, complicated or progressive illness</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">&bull; Hospitalized persons</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">&bull; Persons at higher risk for influenza complications:</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">- Children &lt;2 years of age (highest risk in children &lt;6 months of age)</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">- Adults &ge;65 years of age</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">- Persons with chronic disorders of the pulmonary (including asthma) or cardiovascular systems (except hypertension)</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">- Persons with chronic metabolic diseases (including diabetes mellitus), hepatic disease, renal dysfunction, hematologic disorders (including sickle cell disease), or immunosuppression (including immunosuppression caused by medications or HIV)</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">- Persons with neurologic/neuromuscular conditions (including conditions such as spinal cord injuries, seizure disorders, cerebral palsy, stroke, mental retardation, moderate-to-severe developmental delay, or muscular dystrophy) which may compromise respiratory function, the handling of respiratory secretions, or that can increase the risk of aspiration</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">- Pregnant or postpartum women (&le;2 weeks after delivery)</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">- Persons &lt;19 years of age on long-term aspirin therapy</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">- American Indians and Alaskan Natives</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">- Persons who are morbidly obese (BMI &ge;40)</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">- Residents of nursing homes or other chronic care facilities</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">&bull; Use may also be considered for previously healthy, nonhigh risk outpatients with confirmed or suspected influenza based on clinical judgment when treatment can be started within 48 hours of illness onset.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The ACIP recommends that <b>prophylaxis</b> be considered for the following (see specific antiviral product monograph for appropriate patient selection):</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">&bull; Postexposure prophylaxis may be considered for family or close contacts of suspected or confirmed cases, who are at higher risk of influenza complications, and who have not been vaccinated against the circulating strain at the time of the exposure or if exposure occurred within 2 weeks of vaccination.</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">&bull; Postexposure prophylaxis may be considered for unvaccinated healthcare workers who had occupational exposure without protective equipment.</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">&bull; Pre-exposure prophylaxis should only be used for persons at very high risk of influenza complications and who cannot be otherwise protected at times of high risk for exposure. Prophylaxis should also be administered to all eligible residents of institutions that house patients at high risk when needed to control outbreaks.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7731023\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Relenza may be confused with Albenza, Aplenzin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235703\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Most adverse reactions occurred at a frequency that was less than or equal to the control (lactose vehicle).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills (more common with prophylaxis), dizziness (treatment), fatigue (more common with prophylaxis), headache (more common with prophylaxis), malaise (more common with prophylaxis)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Urticaria (treatment)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain (treatment), anorexia (prophylaxis), decreased appetite (prophylaxis), diarrhea, increased appetite (prophylaxis), nausea (prophylaxis), sore throat (or discomfort; prophylaxis), vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Viral infection (prophylaxis)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, musculoskeletal pain (prophylaxis), myalgia (more common with prophylaxis), rheumatic disease (prophylaxis)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchitis (treatment), cough (more common with prophylaxis), ENT infection, nasal signs and symptoms (more common with prophylaxis), sinusitis (treatment:), rhinitis (prophylaxis), tonsil disease (discomfort or pain; prophylaxis)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever (more common with prophylaxis)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Bronchospasm, cardiac arrhythmia, delusions, dyspnea, hallucination, hypersensitivity reaction (or hypersensitivity-like reaction; includes oropharyngeal edema), impaired consciousness, nightmares, psychiatric disturbance (confusion, delirium, self-injury), seizure, skin rash (including serious cutaneous reactions [eg, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis]), syncope</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235653\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to zanamivir or any component of the formulation (contains milk proteins)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235638\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Allergic reactions: Allergic-like reactions, including anaphylaxis, oropharyngeal edema, and serious skin rashes have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neuropsychiatric events: Rare occurrences of neuropsychiatric events (including confusion, delirium, hallucinations, seizure, and/or self-injury) have been reported, primarily in pediatric patients; may be abrupt  in onset. Direct causation is difficult to establish; influenza infection may also be associated with behavioral and neurologic changes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Respiratory effects: Bronchospasm, including serious cases and some with fatal outcomes, and decreased lung function have been reported in patients with and without airway disease; discontinue with bronchospasm or decreased lung function. For a patient with an underlying airway disease where a medical decision has been made to use zanamivir, a fast-acting bronchodilator should be made available.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Respiratory disease: Not recommended for use in patients with underlying respiratory disease, such as asthma or COPD, due to lack of efficacy in influenza treatment and risk of serious bronchospasm. If zanamivir is prescribed in such patients, closely monitor respiratory function.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Nursing home patients: Effectiveness has not been established for prophylaxis of influenza in nursing home patients (per manufacturer). The CDC recommends zanamivir to be used to control institutional outbreaks of influenza when circulating strains are suspected of being resistant to oseltamivir (refer to current guidelines)  (CDC 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Lactose: Powder for oral inhalation contains lactose; use contraindicated in patients allergic to milk proteins.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Administration: Relenza inhalation powder should only be administered via inhalation using the provided Diskhaler delivery device. The commercially available formulation is a lactose containing powder and is <b>not</b> intended to be solubilized or administered via any nebulizer/mechanical ventilator; inappropriate administration has resulted in death. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Antiviral treatment should begin within 48 hours of symptom onset. However, the CDC recommends that treatment may still be beneficial and should be started in hospitalized patients with severe, complicated or progressive illness if &gt;48 hours. Treatment should not be delayed while awaiting results of laboratory tests for influenza (CDC 2015). Nonhospitalized persons who are not at high risk for developing severe or complicated illness and who have a mild disease are not likely to benefit if treatment is started &gt;48 hours after symptom onset. Nonhospitalized persons who are already beginning to recover do not need treatment (CDC 2011). Safety and efficacy have not been established in patients with significant underlying medical conditions. Not a substitute for annual flu vaccination; has not been shown to reduce risk of transmission of influenza to others. Patients must be instructed in the use of the delivery system. Consider primary or concomitant bacterial infections. Safety and efficacy of repeated courses have not been established.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25819270\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Pediatric patients with influenza may be at increased risk for neuropsychiatric events (confusion, abnormal behavior) and seizures early in their illness; monitor closely.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300233\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235643\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13079&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Influenza Virus Vaccine (Live/Attenuated): Antiviral Agents (Influenza A and B) may diminish the therapeutic effect of Influenza Virus Vaccine (Live/Attenuated).  Management: Avoid anti-influenza antivirals during the period beginning 48 hours prior to and ending 2 weeks after vaccine administration.  Persons receiving these agents within 2 weeks of the live intranasal spray vaccine should receive a repeat vaccine dose.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235645\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235656\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. An increased risk of adverse neonatal or maternal outcomes has not been observed following use of zanamivir during pregnancy. Untreated influenza infection is associated with an increased risk of adverse events to the fetus and an increased risk of complications or death to the mother. Neuraminidase inhibitors are currently recommended for the treatment or prophylaxis of influenza in pregnant women and women up to 2 weeks postpartum (CDC 60[1] 2011; CDC March 13 2014; January 2015).  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7290897\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor respiratory function, changes in behavior; if used for prophylaxis, signs/symptoms of influenza infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235637\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Zanamivir inhibits influenza virus neuraminidase enzymes, potentially altering virus particle aggregation and release.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235652\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Inhalation: Systemic:  ~4% to 17% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding, plasma: &lt;10% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: None </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination, serum: 2.5 to 5.1 hours; Mild to moderate renal impairment: 4.7 hours; Severe renal impairment: 18.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (as unchanged drug); feces (unabsorbed drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2524730\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol powder</b> (Relenza Diskhaler Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/blister (20): $70.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235658\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Relenza (AE, AR, AT, AU, BB, BE, BG, BH, BR, CH, CL, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, HR, IE, IL, IS, IT, JO, KR, KW, LB, LT, LV, MT, MX, MY, NL, NO, NZ, PH, PL, PT, QA, RO, SA, SE, SG, SI, SK, TH, TR, TW, UA, VN, ZW);</li>\n      <li>Virenza (IN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Infectious Diseases, &quot;Antiviral Therapy and Prophylaxis for Influenza in Children,&quot; <i>Pediatrics</i>, 2007, 119(4):852-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zanamivir-pediatric-drug-information/abstract-text/17403862/pubmed\" target=\"_blank\" id=\"17403862\">17403862</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zanamivir-pediatric-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention, (CDC). Recommendations for obstetric health care providers related to use of antiviral medications in the treatment and prevention of influenza. March 13, 2014. Available at <a href=\"http://www.cdc.gov/flu/professionals/antivirals/avrec_ob2011.htm\" target=\"_blank\">http://www.cdc.gov/flu/professionals/antivirals/avrec_ob2011.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR</i>. 2011; 60(1):1-28.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza-Recommendations of the Advisory Committee on Immunization Practices (ACIP),&quot; <i>MMWR Recomm Rep</i>, 2011, 60(1):1-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zanamivir-pediatric-drug-information/abstract-text/21248682/pubmed\" target=\"_blank\" id=\"21248682\">21248682</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). CDC health update regarding treatment of patients with influenza with antiviral medications. January 9, 2015. Available at  <a href=\"http://emergency.cdc.gov/han/han00375.asp%20\" target=\"_blank\">http://emergency.cdc.gov/han/han00375.asp </a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Influenza Antiviral Medications: Summary for Clinicians.&rdquo; Available at <a href=\"http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm\" target=\"_blank\">http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm</a>. Last accessed: November 26, 2012. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention, (CDC). Recommendations for obstetric health care providers related to use of antiviral medications in the treatment and prevention of influenza. March 13, 2014. Available at <a href=\"http://www.cdc.gov/flu/professionals/antivirals/avrec_ob2011.htm\" target=\"_blank\">http://www.cdc.gov/flu/professionals/antivirals/avrec_ob2011.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from  the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. November 6, 2013. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harper SA, Bradley JS, Englund JA, et al, &quot;Seasonal Influenza in Adults and Children - Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management: Clinical Practice Guidelines of the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2009, 48(8):1003-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zanamivir-pediatric-drug-information/abstract-text/19281331/pubmed\" target=\"_blank\" id=\"19281331\">19281331</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Louie JK, Jamieson DJ, Rasmussen SA, et al, &quot;2009 Pandemic Influenza A (H1N1) Virus Infection in Postpartum Women in California,&quot; <i>Am J Obstet Gynecol</i>, 2011, 204(2):144.e1-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zanamivir-pediatric-drug-information/abstract-text/21074132/pubmed\" target=\"_blank\" id=\"21074132\">21074132</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13079 Version 79.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50907065\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F235668\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F235669\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1042836\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1042868\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F235648\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F235634\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F11217378\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1042872\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F235665\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1042837\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F7731023\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F235703\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F235653\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F235638\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25819270\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300233\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F235643\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F235645\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F235656\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F7290897\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F235637\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F235652\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F2524730\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F235658\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13079|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">Zanamivir: Drug information</a></li><li><a href=\"topic.htm?path=zanamivir-patient-drug-information\" class=\"drug drug_patient\">Zanamivir: Patient drug information</a></li></ul></div></div>","javascript":null}